Photocure (LSE:0IMT) - Hisse Senedi Fiyatı, Haberler ve Analizler

0IMT Stoklara Genel Bakış

0IMT temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	3/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 87% daha düşük bir oranda işlem görüyor

Kazançların yılda 94.94% oranında artması öngörülüyor

Bu yıl karlı hale geldi

Risk Analizi

Risk kontrollerimizden 0IMT için herhangi bir risk tespit edilmedi.

Photocure ASA Rakipler

Animalcare Group

AIM:ANCR

UK£148.5m

ECO Animal Health Group

AIM:EAH

UK£43.4m

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

hVIVO

AIM:HVO

UK£136.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Photocure
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	NOK 51.50
52 Haftanın En Yüksek Seviyesi	NOK 71.90
52 Haftanın En Düşük Seviyesi	NOK 48.05
Beta	0.99
11 Aylık Değişim	-2.83%
3 Aylık Değişim	3.00%
1 Yıllık Değişim	2.80%
33 Yıllık Değişim	-46.52%
5 Yıllık Değişim	-40.22%
Halka arzdan bu yana değişim	13.19%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0IMT	GB Pharmaceuticals	GB Pazar
7D	-1.5%	5.0%	2.2%
1Y	2.8%	2.5%	8.8%

Getiri vs. Endüstri: 0IMT geçen yıl boyunca % 2.5 oranında getiri sağlayan UK Pharmaceuticals sektörüyle eşleşti.

Getiri vs Piyasa: 0IMT geçen yıl % 8.8 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0IMT's price volatile compared to industry and market?
0IMT volatility
0IMT Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0IMT son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 0IMT 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1993	102	Dan Schneider	www.photocure.com

Photocure ASA, bağlı ortaklıkları ile birlikte İskandinav ülkeleri, Almanya, Fransa, Avusturya, Birleşik Krallık, BeNeLux, İtalya, diğer Avrupa Ülkeleri, Kanada ve Amerika Birleşik Devletleri'nde farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi, dağıtımı, pazarlanması ve satışı ile ilgilenmektedir. Ticari Franchise ve Geliştirme Portföyü segmentleri aracılığıyla faaliyet göstermektedir. Şirket, mesane kanserinin tespiti ve yönetimi için Hexvix/Cysview'i sunmaktadır.

Photocure ASA Temel Bilgiler Özeti

Photocure'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0IMT temel i̇stati̇sti̇kler
Piyasa değeri	NOK 1.31b
Kazançlar(TTM)	NOK 14.16m
Gelir(TTM)	NOK 526.25m

92.6x

F/K Oranı

2.5x

P/S Oranı

0IMT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0IMT gelir tablosu (TTM)
Gelir	NOK 526.25m
Gelir Maliyeti	NOK 29.11m
Brüt Kâr	NOK 497.15m
Diğer Giderler	NOK 482.98m
Kazançlar	NOK 14.16m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.52
Brüt Marj	94.47%
Net Kâr Marjı	2.69%
Borç/Özkaynak Oranı	0%

0IMT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0IMT Stoklara Genel Bakış

Ödüller

Risk Analizi

Photocure ASA Rakipler

AIM:ANCR

UK£148.5m

AIM:EAH

UK£43.4m

LSE:HIK

UK£4.4b

AIM:HVO

UK£136.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Recent updates

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Full year 2023 earnings released: EPS: kr0.01 (vs kr2.66 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Second quarter 2023 earnings released: EPS: kr0.16 (vs kr0.68 loss in 2Q 2022)

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Insufficient new directors

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

First quarter 2022 earnings released: kr0.82 loss per share (vs kr0.57 profit in 1Q 2021)

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) announces an Equity Buyback for 2,682,006 shares, representing 10% of its issued share capital.

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında